Edwards Lifesciences initiated with an Outperform, target $152 at Raymond James. Raymond James analyst Jayson Bedford initiated Edwards Lifesciences with an Outperform and $152 price target saying it is the dominant player in attractive end markets with favorable competitive dynamics. The analyst expects Edwards’ R&D investment, which is well above peers, to maintain market leadership, for the TAVR market to grow in double-digits, and new product introductions and indication expansion to be near-term drivers of growth. Bedford’s analyst are slightly above consensus and expects modest multiple expansion and mitral progress to drive stock outperformance
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.